Tivantinib: critical review with a focus on hepatocellular carcinoma

Bibliography

• Ferlay J, Shin HE, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43
   PubMed Web of Science ®Google Scholar
• Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalysis of a phase III trial. J Hepatol 2012;57(4):821-9
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;12(12):3657-60
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4(12):915-25
   PubMed Web of Science ®Google Scholar
• Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22(4):309-25
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-45
   PubMed Web of Science ®Google Scholar
• Ke AW, Shi GM, Zhou J, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009;49(2):491-503
   PubMed Web of Science ®Google Scholar
• Osada S, Kanematsu M, Imai H, et al. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 2008;55:544-9
   PubMed Web of Science ®Google Scholar
• You H, Ding W, Dang H, et al. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011;54(3):879-89
   PubMed Web of Science ®Google Scholar
• Jahangiri A, De Lay M, Miller LM, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 2013;19(7):1773-83
   PubMed Web of Science ®Google Scholar
• Piscaglia AC, et al. 2009 AASLD Annual Meeting
   Google Scholar
• Tesio M, Golan K, Corso S, et al. Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood 2011;117(2):419-28
   PubMed Web of Science ®Google Scholar
• Coudriet GM, He J, Trucco M, et al. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. PLoS One 2010;5(11):e15384
   Google Scholar
• Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213(2):316-25
   PubMed Web of Science ®Google Scholar
• Eathiraj S, Palma R, Volckova E, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011;286(23):20666-76
   PubMed Web of Science ®Google Scholar
• Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9(6):1544-53
   PubMed Web of Science ®Google Scholar
• Chen CR, et al. 2009 AACR Annual Meeting; abstract 820
   Google Scholar
• Simonelli M, Rodriguez-Lope C, Rimassa L, et al. Biomarker results from ARQ 197-114: a phase 1b trial evaluating the c-MET inhibitor ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC). Ann Oncol 2010;21(8s):abstrsct 196p
   Google Scholar
• Cheng CR, et al. AACR 2009;abstract 820
   Google Scholar
• Trojan J, Zeuzem S. Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs 2013;22(1):141-7
   PubMed Web of Science ®Google Scholar
• Rimassa L, Personeni N, Simonelli M, et al. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncol 2013;9(2):153-65
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31:4067-75
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009;10:794-800
   PubMed Web of Science ®Google Scholar
• Zhu A, Sahani DV, Duda DG, et al. Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-35
   PubMed Web of Science ®Google Scholar
• Johnson P, Qin SK, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the phase 3 BRISK-FL Study. Hepatology 2012;56:1519-20A
   Web of Science ®Google Scholar
• Cainap C, Qin S, Huang I, et al. Phase 3 trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). ESMO 2012. Available from: www.clinicaltrials.gov:NCT01009593
   Google Scholar
• Zhu AX, Rosmorduc O, Evans J, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). ESMO 2012. Available from: www.clinicaltrials.gov:NCT00901901
   Google Scholar
• Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. J Clin Oncol 2013;31:3509-16
   PubMed Web of Science ®Google Scholar
• Llovet JM, Peña CE, Lathia CD, et al. SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18(8):2290-300
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12(2):89-103
   PubMed Web of Science ®Google Scholar
• Lü S, Rizzani A, Kolligs F, et al. Antitumor efficacy of the c-met inhibitor tivantinib (ARQ-197) in liver cancer cells: effects on apoptosis and cell cycle. Abstract to be presented at the 2012 GASL conference
   Google Scholar
• Katayama R, Aoyama A, Yamori T, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013;73(10):3087-96
   PubMed Web of Science ®Google Scholar
• Basilico C, Pennacchietti S, Vigna E, et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013;19(9):2381-92
   PubMed Web of Science ®Google Scholar
• Chen CR, Szwaya J, Rojnukarin A, et al. Combination studies of tyrosine kinase inhibitors (TKIs): assessment of potential cytotoxic synergy of ARQ 197 with sorafenib or sunitinib [abstract 820]. Presented at: 100th American Association for Cancer Research Annual Meeting; 18 – 22 April 2009; Denver, CO, USA. 2009
   Google Scholar
• Previdi S, Abbadessa G, Dalò F, et al. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 2012;11(1):214-23
   PubMed Web of Science ®Google Scholar
• Rosen LS, Senzer N, Mekhail T, et al. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 2011;17(10):3087-96
   Google Scholar
• Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29(10):1271-9
   PubMed Web of Science ®Google Scholar
• Goldman J, Laux I, Chai F, et al. Phase I dose escalation trial evaluating the combination of the selective MET (Mesenchymal-Epithelial Transition factor) inhibitor Tivantinib (ARQ 197) plus Erlotinib. Cancer 2012;118(23):5903-11
   PubMed Web of Science ®Google Scholar
• Adjei AA, et al. Efficacy in selected tumor types in a phase I study of the c-MET inhibitor Tivantinib (ARQ 197) in combination with sorafenib. J Clin Oncol 2011;29(Suppl):abstract 3034
   Google Scholar
• Pant S, Saleh M, Bendell J, et al. Phase Ib dose escalation trial evaluating c-MET inhibitor ARQ 197 plus gemcitabine in patients with advanced solid tumors on schedules refined by in vitro mechanistic studies [abstract 510P]. Ann Oncol 2010;21(Suppl 8):viii167
   Google Scholar
• Santoro A, Simonelli M, Rodriguez-Lope C, et al. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 2013;108(1):21-4
   PubMed Web of Science ®Google Scholar
• Savage RE, Zhong C, Hall T, et al. In vitro ADME Properties of ARQ 197. Comparison to in vivo data [poster 1291]. Presented at: 99th American Association for Cancer Research Annual Meeting; 11 – 15 April 2008; Philadelphia, PA, USA
   Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
   PubMed Web of Science ®Google Scholar
• Eng C, et al. Phase I study of tivantinib (ARQ 197), Irinotecan and Cetuximab in patients with K-RAS wild-type, previously treated, metastatic colorectal cancer [abstract PD-0018]. Ann Oncol 2012;23(Suppl 4):iv19-30
   Google Scholar
• Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-74
   PubMed Web of Science ®Google Scholar
• Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of Erlotinib plus Tivantinib versus Erlotinib plus Placebo in previously treated non small cell lung cancer. J Clin Oncol 2011;29(24):3307-15
   PubMed Web of Science ®Google Scholar
• Rodig S, Sequist LV, Schiller JH, et al. An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded Phase 2 study. Cancer Res 2012;72(8 Suppl 1):abstract 1729
   Google Scholar
• Scagliotti GV, Novello S, Schiller JH, et al. Rationale and design of MARQUEE: a phase III randomized, double-blind study of Tivantinib plus Erlotinib versus Placebo plus Erlotinib in previously treated patients with locally advanced or metastatic nonsquamous non-small cell lung cancer. Clin Lung Cancer 2012;13(5):391-5
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Phase 3, randomized, double-blinded, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib. Available from: http://clinicaltrial.gov/ct2/show/NCT01377376
   Google Scholar
• Novello S, Scagliotti GV, Ramlau R, et al. Efficacy analysis for molecular subgroups in MARQUEE: a randomized, double-blind, placebo-controlled, phase III trial of Tivantinib (ARQ-197) plus Erlotinib versus Placebo plus Erlotinib in previously treated patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). Proc World Conference on Lung Cancer (WCLC); 2013
   Google Scholar
• Scagliotti GV, Novello S, Ramlau R, et al. MARQUEE: a randomized, double-blind, placebo-controlled, phase III trial of Tivantinib (ARQ-197) plus Erlotinib versus Placebo plus Erlotinib in previously treated patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). Proc of European Congress on Clinical Oncology (ECCO); 2013
   Google Scholar
• Inno A, Di Salvatore M, Cenci T, et al. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 2011;10(4):325-32
   PubMed Web of Science ®Google Scholar
• Eng C, et al. A randomized, placebo-controlled, phase 2 study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan as second-line therapy in patients (pts) with K-RAS wild type (WT) metastatic colorectal cancer (CRC). J Clin Oncol 2013;31(Suppl):abstract 3508
   Google Scholar
• Martell R, et al. Safety and efficacy of MET inhibitor Tivantinib (ARQ 197) combined with sorafenib in patients with hepatocellular carcinoma (HCC) from a phase I study. J Clin Oncol 2012;30s:abstract 4117
   Google Scholar
• Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013;14(1):55-63
   PubMed Web of Science ®Google Scholar
• Daniele B, et al. Ann Oncol 2012(Suppl 9):abstract 536
   Google Scholar
• ClinicalTrials.gov. A Phase 3, randomized, double-blind study of tivantinib (ARQ 197) in subjects with MET diagnostic-high inoperable hepatocellular carcinoma treated with one prior systemic therapy. Available from: http://clinicaltrial.gov/ct2/show/NCT01755767
   Google Scholar
• Press Release from Arqule Feb 4, 2014. Announcement of initiation of a Phase III clinical trial evaluating tivantinib (ARQ 197) in Japanese patients with c-MET diagnostic high inoperable HCC prior sorafenib therapy
   Google Scholar
• Press Release from Arqule Jan 16,2014. Update on clinical trials in hepatocellular carcinoma and non-small-cell lung cancer with tivantinib
   Google Scholar
• Villanueva A, Llovet JM. Liver cancer 2013: mutational landscape of HCC - the end of the beginning. Nat Rev Clin Oncol 2014;11:73-4
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A phase 3, randomized, double-blind, controlled study of cabozantinib (XL184) vs placebo I subjects with hepatocellular carcinoma who have received prior sorafenib. Available from: http://clinicaltrial.gov/ct2/show/NCT01908426
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrial.gov [Accessed 19 January 2014]
   Google Scholar